This review will highlight the survival impact that rituximab therapy has had on major lymphoid malignancies, such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. We will also discuss alternative anti-CD20 monoclonal antibodies.
Given the benefit of rituximab to patients, it will be important that the use of biosimilar compounds not compromise the efficacy of treatment. However, measures to improve access to anti-CD20 therapy in a cost-effective manner will clearly provide benefit to patients with lymphoma.
There is considerable value in having achieved a minimal residual disease negativity for pediatric and adult patients with acute lymphoblastic leukemia.
Insurance status at the time of chronic myeloid leukemia diagnosis appears to have an influence on survival outcomes, with the uninsured and those on Medicaid having worse overall survival.
Patients with myelodysplastic syndrome undergoing a reduced–intensity conditioning regimen prior to allogeneic stem-cell transplantation had similar 2-year survival outcomes as patients who underwent myeloablative conditioning.
It is increasingly important that nurses recognize cytokine release syndrome and other side effects that can be triggered by treatment with engineered CAR T-cell therapies.
Female survivors of childhood acute lymphoblastic leukemia were at risk for neurocognitive impairment and were more susceptible to the effects of sleep disturbance and fatigue compared with their male counterparts.
Patients undergoing allo-HSCT can remain immune-impaired for several years after treatment, but methods such as adopting guideline-driven tracking tools to determine which patients have been assessed for immunization eligibility can improve vaccination rates, suggest a feasibility study at ONS.
Maintenance lenalidomide significantly prolonged progression-free survival in elderly patients with diffuse large B-cell lymphoma who responded to first-line R-CHOP.
Single-agent use of blinatumomab resulted in anti-leukemic activity in patients with tyrosine kinase inhibitor–relapsed or refractory Philadelphia chromosome positive B-precursor acute lymphoblastic leukemia.